Ireland
--:--IST
Recruiting Not applicable

Bronchial Blockers vs Double-Lumen Tubes in Obese Patients

NCT07031986 · tracked via the Priya Life Science Spain tracker
Sponsor
Paulo Andrés Cano Jiménez
Phase
Not applicable
Started
2024-08-15
Last updated
2025-06-22

Condition(s) studied

One-lung Ventilation

Investigational drug(s) / intervention(s)

One-Lung ventilation with Double-Lumen TubeOne-Lung Ventilation with Bronchial Blocker

One-Lung ventilation with Double-Lumen Tube: To achieve the required one-lung ventilation during lung resection, patients will be managed with a double-lumen tube.

One-Lung Ventilation with Bronchial Blocker: To achieve the required one-lung ventilation during lung resection, patients will be managed with a bronchial blocker.

Study summary

The goal of this clinical trial is to evaluate the efficacy of bronchial blockers and double-lumen tubes in achieving one-lung ventilation in obese patients undergoing lung resections. The primary question it aims to answer is:

• Is intraoperative hypoxia significantly different depending on the device used?

Researchers will compare the use of bronchial blockers and double-lumen tubes to assess differences in efficacy and safety.

Participants will not be required to perform any tasks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * BMI ≥ 30 kg/m2 * Diagnostic or clinical suspicion of lung cancer * Lung resection surgery (lobectomy, segmentectomy or wedge resection) by VATS or thoracotomy, requiring one-lung ventilation. * Use of bronchial blocker or double-lumen tube for one-lung ventilation. Exclusion Criteria: * Patients with evident anatomic alterations, in which double-lumen tubes may be contraindicated. * Emergency surgeries.

Primary outcome measure(s)

  • Hypoxia — Intraoperative (both from anesthetic induction to one-lung ventilation, and during one-lung ventilation)
    While its definition is somewhat arbitrary, the investigators consider hypoxia as SpO₂ \< 90%, while maintaining FiO₂ = 1.0, in accordance to our hospital guidelines.

Trial sites (1)

FacilityCityRegionStatus
Hospital Son Espases Palma de Mallorca Balearic Islands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07031986 on ClinicalTrials.gov ↗ ← All trials in Spain